Burning Rock Biotech (NASDAQ:BNR) Shares Up 0.4%

Burning Rock Biotech Limited (NASDAQ:BNR) shot up 0.4% on Tuesday . The stock traded as high as $7.15 and last traded at $6.87. 155 shares changed hands during trading, a decline of 97% from the average session volume of 4,583 shares. The stock had previously closed at $6.84.

Burning Rock Biotech Stock Up 0.4 %

The company has a fifty day moving average of $6.98 and a two-hundred day moving average of $7.67. The stock has a market capitalization of $70.35 million, a price-to-earnings ratio of -1.06 and a beta of 0.17.

Burning Rock Biotech (NASDAQ:BNR) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.16) earnings per share for the quarter. Burning Rock Biotech had a negative return on equity of 71.22% and a negative net margin of 113.39%. The company had revenue of $17.40 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Burning Rock Biotech stock. Kynam Capital Management LP grew its stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR) by 10.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,640,914 shares of the company’s stock after purchasing an additional 946,488 shares during the period. Burning Rock Biotech makes up about 0.7% of Kynam Capital Management LP’s holdings, making the stock its 18th largest position. Kynam Capital Management LP owned about 9.41% of Burning Rock Biotech worth $7,020,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.